

VARIAN MEDICAL SYSTEMS INC

Form 8-K

May 29, 2018

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported) **May 24, 2018**

VARIAN MEDICAL SYSTEMS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	1-7598	94-2359345
(State or Other Jurisdiction (Commission File (IRS Employer		
of Incorporation)	Number)	Identification No.)

3100 Hansen Way, Palo Alto, CA	94304-1030
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code **(650) 493-4000**

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Edgar Filing: VARIAN MEDICAL SYSTEMS INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

Item 8.01. Other Events.

On May 25, 2018 (Sydney time), Varian Medical Systems, Inc. (the “**Company**”) made an application in the Federal Court of Australia (the “**Court**”) seeking orders that the shareholder meeting to approve the scheme of arrangement between Sirtex and Varian (“**Varian Scheme**”) be reconvened on May 31, 2018.

The Court indicated that it anticipates it will make orders consistent with the timetable submitted by Sirtex, which includes relisting the proceedings concerning the Varian Scheme before the Court on July 3, 2018 for the purpose of considering whether to approve supplementary disclosure to be sent to shareholders in relation to the Varian Scheme.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Varian
Medical
Systems,
Inc.

By: /s/ John W. Kuo
Name: John W. Kuo
Senior Vice
President,
General Counsel
Title: and

Corporate
Secretary

Dated: May 29, 2018